Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2015-01-14

Original market date: See footnote 1

2006-09-08

Product name:

KALETRA

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section .

DIN:

02285533

Product Monograph/Veterinary Labelling:

Date: 2019-09-27 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company: 

ABBVIE CORPORATION
8401 Trans-Canada Highway
Saint-Laurent
Quebec
Canada  H4S 1Z1

Class: 

Human

Dosage form(s):

Tablet

Route(s) of administration:

Oral

Number of active ingredient(s):

2

Schedule(s):

Prescription  

Biosimilar Biologic Drug:

No

American Hospital Formulary Service (AHFS): See footnote 3

08:18.08.08   HIV PROTEASE INHIBITORS

Anatomical Therapeutic Chemical (ATC): See footnote 4

J05AR10  LOPINAVIR AND RITONAVIR

Active ingredient group (AIG) number:See footnote 5

0243421003

List of active ingredient(s)
Active ingredient(s) Strength
LOPINAVIR 200 MG
RITONAVIR 50 MG

Application information

Related information

Contact us

Version 3.7.1
Date modified: